

Special Issue

Personalized Medicine Based on Drug Transporter Genetic Heterogeneity

Message from the Guest Editors

The International Transporter Consortium (ITC) has indicated the need to implement easy and reproducible preclinical assays suitable for the analysis of drug-transporter interactions and drug–drug interactions likely to compromise drug pharmacokinetics and pharmacodynamics. These cross-interactions have been shown, in some cases, to have a clinical impact and may be also modulated by genetic polymorphisms in the transporter-encoding genes. The two major transporter-encoding gene superfamilies in humans, *SLC* and *ABC*, include paradigms of genetic heterogeneity, although their impact on drug action and their suitability as biomarkers of individual drug-response heterogeneity have not been properly addressed thus far. The *Journal of Personalized Medicine* is now opening a Special Issue that is fully devoted to drug transporter functional heterogeneity, with a call for papers involving basic, translational, and clinical research on this topic.

Guest Editors

Prof. Dr. Marçal Pastor-Anglada

1. Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain
2. Pediatric Oncology Program, Institut de Recerca Sant Joan de Déu (IR SJD), Esplugues de Llobregat, Barcelona, Spain
3. Oncology Program, National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD), Instituto de Salud Carlos III, Madrid, Spain

Prof. Dr. Matthias Schwab

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology and Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA), University Hospital, Tuebingen Auerbachstrasse 112, 70376 Stuttgart, Germany

Deadline for manuscript submissions

closed (15 February 2019)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/9128

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).